Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Background/Aims: Sorafenib is the first approved systemic treatment for advanced hepatocellular carcinoma (HCC). However, its clinical utility is limited, especially in Asian countries. Several reports have suggested the survival benefits of hepatic arterial infusion chemotherapy (HAIC) for advanced HCC with main portal vein tumor thrombosis (PVTT). This study aimed to compare the efficacy of sorafenib-based therapy with that of HAIC-based therapy for advanced HCC with main PVTT. Methods: Advanced HCC patients with main PVTT treated with sorafenib or HAIC between 2008 and 2016 at Korea University Medical Center were included. We evaluated overall survival (OS), time-to-progression (TTP), and the disease control rate (DCR). Results: Seventy-three patients were treated with sorafenib (n=35) or HAIC (n=38). Baseline characteristics were not significantly different between groups, except the presence of solid organ metastasis (46% vs 5.3%, p<0.001). The median OS time was not significantly different between the groups (6.4 months vs 10.0 months, p=0.139). TTP was longer in the HAIC group than in the sorafenib group (2.1 months vs 6.2 months, p=0.006). The DCR was also better in the HAIC group than in the sorafenib group (37% vs 76%, p=0.001). Subgroup analysis, which excluded patients with extrahepatic solid organ metastasis, showed the same trends for the median OS time (8.8 months vs 11.1 months, p=0.097), TTP (1.9 months vs 6.0 months, p<0.001), and DCR (53% vs 81%, p=0.030). Conclusions: HAIC-based therapy may be an alternative to sorafenib for advanced HCC with main PVTT by providing longer TTP and a better DCR.
Abstract
Background/Aims: Sorafenib is the first approved systemic treatment for advanced hepatocellular carcinoma (HCC). However, its clinical utility is limited, especially in Asian countries. Several reports have suggested the survival benefits of hepatic arterial infusion chemotherapy (HAIC) for advanced HCC with main portal vein tumor thrombosis (PVTT). This study aimed to compare the efficacy of sorafenib-based therapy with that of HAIC-based therapy for advanced HCC with main PVTT. Methods: Advanced HCC patients with main PVTT treated with sorafenib or HAIC between 2008 and 2016 at Korea University Medical Center were included. We evaluated overall survival (OS), time-to-progression (TTP), and the disease control rate (DCR). Results: Seventy-three patients were treated with sorafenib (n=35) or HAIC (n=38). Baseline characteristics were not significantly different between groups, except the presence of solid organ metastasis (46% vs 5.3%, p<0.001). The median OS time was not significantly different between the groups (6.4 months vs 10.0 months, p=0.139). TTP was longer in the HAIC group than in the sorafenib group (2.1 months vs 6.2 months, p=0.006). The DCR was also better in the HAIC group than in the sorafenib group (37% vs 76%, p=0.001). Subgroup analysis, which excluded patients with extrahepatic solid organ metastasis, showed the same trends for the median OS time (8.8 months vs 11.1 months, p=0.097), TTP (1.9 months vs 6.0 months, p<0.001), and DCR (53% vs 81%, p=0.030). Conclusions: HAIC-based therapy may be an alternative to sorafenib for advanced HCC with main PVTT by providing longer TTP and a better DCR.
참고문헌 (33)
- European Association for the Study of the Liver, "EASL Clinical Practice Guidelines : management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
- Global Burden of Disease Liver Cancer Collaboration, "The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level : results from the global burden of disease study 2015", JAMA Oncol, 3, pp.1683~1691 (2017)
- Cheng AL, "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma : a phase III randomised, double-blind, placebo-controlled trial", Lancet Oncol, 10, pp.25~34 (2009)
- Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
- Yim HJ, "Current management of hepatocellular carcinoma : an Eastern perspective", World J Gastroenterol, 21, pp.3826~3842 (2015)
- Lencioni R, "First interim analysis of the GIDEON(Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib)non-interventional study", Int J Clin Pract, 66, pp.675~683 (2012)
- Kim HY, "Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma", J Gastroenterol Hepatol, 28, pp.1756~1761 (2013)
- Kudo M, "Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma : a single-center experience", Dig Dis, 30, pp.609~616 (2012)
- Pressiani T, "Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma : a prospective feasibility analysis", Ann Oncol, 24, pp.406~411 (2013)
- Tsukui Y, "Factors contributing to the overall survival in patients with hepatocellular carcinoma treated by sorafenib", Hepatogastroenterology, 59, pp.2536~2539 (2012)
- Woo HY, "Clinical course of sorafenib treatment in patients with hepatocellular carcinoma", Scand J Gastroenterol, 47, pp.809~819 (2012)
- Ikeda M, "A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis", Cancer Chemother Pharmacol, 72, pp.463~470 (2013)
- Jeong SW, "The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma", Asia Pac J Clin Oncol, 8, pp.164~171 (2012)
- Kim BK, "Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma", J Cancer Res Clin Oncol, 137, pp.659~667 (2011)
- Miyaki D, "Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification", J Gastroenterol Hepatol, 27, pp.1850~1857 (2012)
- Song DS, "Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis", World J Gastroenterol, 19, pp.4679~4688 (2013)
- Woo HY, "A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma", Cancer Chemother Pharmacol, 65, pp.373~382 (2010)
- Lencioni R, "Modified RECIST(mRECIST)assessment for hepatocellular carcinoma", Semin Liver Dis, 30, pp.52~60 (2010)
- Llovet JM, "Design and endpoints of clinical trials in hepatocellular carcinoma", J Natl Cancer Inst, 100, pp.698~711 (2008)
- "Common Terminology Criteria for Adverse Events v5.0"[URL]
- Cheung TK, "Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong", Aliment Pharmacol Ther, 24, pp.573~583 (2006)
- Llovet JM, "Natural history of untreated nonsurgical hepatocellular carcinoma : rationale for the design and evaluation of therapeutic trials", Hepatology, 29, pp.62~67 (1999)
- Minagawa M, "Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus", World J Gastroenterol, 12, pp.7561~7567 (2006)
- Schöniger-Hekele M, "Hepatocellular carcinoma in Central Europe : prognostic features and survival", Gut, 48, pp.103~109 (2001)
- Peck-Radosavljevic M, "Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma", Eur J Gastroenterol Hepatol, 22, pp.391~398 (2010)
- Fan J, "Multimodality treatment in hepatocellular carcinoma patients with tumor thrombi in portal vein", World J Gastroenterol, 7, pp.28~32 (2001)
- 오명진, "Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as firstline therapy", Clinical and Molecular Hepatology, 19(3), pp.288~299 (2013), 대한간학회[DOI]
- Woo HY, "New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis", Clin Mol Hepatol, 21, pp.115~121 (2015)
- Choi JH, "Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis", Cancer Chemother Pharmacol, 82, pp.469~478 (2018)
- Song DS, "A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis", J Gastroenterol, 50, pp.445~454 (2015)
- Kudo M, "Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma : a randomised phase 3 non-inferiority trial", Lancet, 391, pp.1163~1173 (2018)
- Abou-Alfa GK, "Cabozantinib in patients with advanced and progressing hepatocellular carcinoma", N Engl J Med, 379, pp.54~63 (2018)
- Bruix J, "Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE) : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet, 389, pp.56~66 (2017)